Clinical Trial Update: Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating subcutaneous talquetamab in elderly patients with early-relapse multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Talquetamab (talquetamab)

Snippet

Sponsor: Larysa Sanchez | Conditions: Multiple Myeloma in Relapse | Phase 2 | Status: RECRUITING